A Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-61803534 and an Open-Label Study to Evaluate the Effect of JNJ-61803534 on the Pharmacokinetics of Midazolam in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs JNJ-61803534 (Primary) ; Midazolam
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 09 Nov 2017 Planned number of patients changed from 108 to 124.
- 09 Nov 2017 Planned End Date changed from 20 Jun 2018 to 20 Nov 2018.
- 09 Nov 2017 Planned primary completion date changed from 7 Dec 2017 to 1 Sep 2018.